In vitro and intracellular antibacterial activities of OPC-167832 against Mycobacterium fortuitum
10.3969/j.issn.1002-2694.2025.00.057
- VernacularTitle:OPC-167832对偶发分枝杆菌的体外和胞内抑菌活性评价
- Author:
Zhen-yan QI
1
;
Xia YU
1
;
Hai-rong HUANG
1
;
Hong-fei DUAN
1
Author Information
1. 首都医科大学附属北京胸科医院,北京 101149
- Publication Type:Journal Article
- Keywords:
Mycobacterium fortuitum;
non-tuberculous mycobacterium;
DprE1 inhibitor;
OPC-167832;
in vitro
- From:
Chinese Journal of Zoonoses
2025;41(4):392-397
- CountryChina
- Language:Chinese
-
Abstract:
This study evaluated the potential of OPC-167832 as a new method for the treatment of Mycobacterium fortuitum infec-tion.Drug sensitivity tests were conducted with the broth microdilution method to determine the minimum inhibitory concentration(MIC)of OPC-167832 against standard strains of M.fortuitum and 44 clinical isolates of M.fortuitum.A DprE1 overexpression strain was constructed,and the effect in the MIC of OPC-167832 against M.fortuitum were explored.Intracellular germicidal tests and checkerboard tests were conducted to verify the ability of OPC-167832 to kill intracellular M.fortuitum,and its interaction with five drugs:amikacin,clarithromycin,imipenem,moxifloxacin,and clofazimine.The MIC50 and MIC90 against 44 clinical isolates of M.fortuitum were 0.031 25 μg/mL and 0.062 5μg/mL,respectively.The epidemiological cut-off value(ECOFF)was 0.062 5 μg/mL.Overexpression of DprE1 led to resistance to OPC-167832 in M.fortuitum.After 24 hours of incubation,the intracellular bacterial in-hibition rate of OPC-167832 at a 1 μg/mL concentration was 81.37%,exceeding the 74.05%inhibition rate of amikacin at a 1 μg/mL concentration.OPC-167832 showed strong inhibitory activity against M.fortuitum in vitro and in macrophages,and might provide a promising treatment for M.fortuitum infection.
